The growth of Endoscopic Retrograde Cholangiopancreatography Market is majorly attributed to factors such as the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries. On the other hand, the high costs of endoscopic retrograde cholangiopancreatography devices, the development of other procedures like EUS and MRCP, and the shortage of trained physicians and endoscopists are factors expected to restrain the market growth to a certain extent.
The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3
billion in 2021, at a CAGR of 9.6% during the forecast period.
Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170242954
Market Segmentation
Based on products, the ERCP market has been
segmented into endoscopes, endotherapy devices, visualization systems, energy
devices, and others. The factors attributing to the large revenue of the
endotherapy devices segment include the growing preference for minimally
invasive surgeries and the increasing prevalence of gastrointestinal
conditions.
In the endotherapy devices segment, sphincterotomes
accounted for the largest market share during the forecast period. This can be
attributed to the increasing incidence of pancreatic duct and bile duct stones
and the growing geriatric population leading to an increase in biliary
disorders.
Regional Analysis:
North
America accounted for the largest share of the ERCP
market in 2020. The increasing prevalence of cancer, high investments by
hospitals to purchase new ERCP equipment, and a strong focus on research
activities to improve endoscopy techniques are the major factor contributing to
this.
Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=170242954
Top Key Players:
The major players in the global endoscopic
retrograde cholangiopancreatography market include Olympus Corporation (Japan),
CONMED Corporation (US), Fujifilm Holdings Corporation (Japan),
HOYA Corporation (Japan), KARL STORZ SE &
Co. KG (Germany),
Ambu A/S (Denmark),
Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC
(Ireland),
Cook Medical (US), and B. Braun Melsungen AG (Germany).
No comments:
Post a Comment